Price movement over the last 24 hours
Alcon AG vs Bumble Inc — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Bumble Inc trades at $3.02 (market cap $409.55M). The key difference: Alcon AG is far larger — about 79.8× Bumble Inc's market cap, and Alcon AG pays a 0.54% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.
| ALC | BMBL | |
|---|---|---|
Market Cap | $32.69B | $409.55M |
Sector | Health | Technology |
52-Week High | $92.22 | $8.57 |
52-Week Low | $62.02 | $2.70 |
Enterprise Value | $36.28B | $761.23M |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Bumble (BMBL) trades at $3.12, down 4.88% on the day, reflecting ongoing investor concerns despite recent earnings beats. The stock shows a bullish technical signal with mixed oscillators, while fundamentally the company maintains a high gross margin of 71.75% but suffers from significant net losses (-71.04% margin). Recent news indicates strategic shifts including AI integration and potential sale exploration as the company addresses declining paid users and competitive pressures.
Bumble presents a high-risk opportunity with potential upside to the $4.37 analyst target, though execution risks remain severe. The company's valuation multiples appear attractive (P/S 0.4x, P/B 0.67x) but must be weighed against persistent profitability challenges and user base declines. Success hinges on the upcoming platform overhaul and AI initiatives reversing negative trends.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →